Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 8, 2011, Pages 951-953

  Shimada, Akira ^a   Shigihara, Toshikatsu ^a   Okubo, Yoshiaki ^a   Katsuki, Takeshi ^a   Yamada, Yoshifumi ^a   Oikawa, Yoichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Metformin; Pioglitazone; Slowly progressive type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SLOWLY PROGRESSIVE TYPE 1 DIABETES MELLITUS; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 80855131145     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1235     Document Type: Article

References (6)

1. Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2115-2121.
2. Shigihara T, Okubo Y, Kanazawa Y, Oikawa Y, Shimada A. Thiazolidinediones may not reduce diabetes incidence in type 1 diabetes. Ann N Y Acad Sci 2006; 1079: 365-368.
3. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314-317.
4. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007; 86: S858-S866.
5. Kawano Y, Irie J, Nakatani H, Yamada S. Pioglitazone might prevent the progression of slowly progressive type 1 diabetes. Intern Med 2009; 48: 1037-1039.
6. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-1293.